Dapagliflozin in patients with type 2 diabetes mellitus: A pooled analysis of safety data from phase IIb/III clinical trials

AIM: To evaluate the safety and tolerability of dapagliflozin, a highly selective sodium‐glucose co‐transporter‐2 inhibitor, in patients with type 2 diabetes mellitus (T2DM). METHODS: Data were pooled from 13 placebo‐controlled trials of up to 24 weeks’ duration (dapagliflozin, n = 2360; placebo, n ...

Descripción completa

Detalles Bibliográficos
Autores principales: Jabbour, Serge, Seufert, Jochen, Scheen, Andre, Bailey, Clifford J., Karup, Cathrina, Langkilde, Anna M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Blackwell Publishing Ltd 2017
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5836959/
https://www.ncbi.nlm.nih.gov/pubmed/28950419
http://dx.doi.org/10.1111/dom.13124

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5836959/
https://www.ncbi.nlm.nih.gov/pubmed/28950419
http://dx.doi.org/10.1111/dom.13124

Ejemplares similares